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Abstract
In this study we propose a novel bacterial vaccine strategy where non-pathogenic bacteria are complemented with traits
desirable for the induction of protective immunity. To illustrate the proof of principle of this novel vaccination strategy, we
use the model organism of intracellular immunity Listeria. We introduced a, low copy number BAC-plasmid harbouring the
virulence gene cluster (vgc) of L. monocytogenes (Lm) into the non-pathogenic L. innocua (L.inn) strain and examined for its
ability to induce protective cellular immunity. The resulting strain (L.inn::vgc) was attenuated for virulence in vivo and
showed a strongly reduced host detrimental inflammatory response compared to Lm. Like Lm, L.inn::vgc induced the
production of Type I Interferon’s and protection was mediated by Listeria-specific CD8+ T cells. Rational vaccine design
whereby avirulent strains are equipped with the capabilities to induce protection but lack detrimental inflammatory effects
offer great promise towards future studies using non-pathogenic bacteria as vectors for vaccination.
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Introduction
Current state of the art vaccine technology focuses on three
distinct strategies 1) the creation of live attenuated pathogens
based on the deletion of virulence factors [1] 2) the use of subunit
vaccines [2] which contain one or more semi-pure antigens that
are critical in inducing an immune response and 3) the use of
metabolically active but non-viable bacteria [3].
For the first strategy, it must be considered that in today’s
medicine vaccines will often be administered to immunocompro-
mised individuals and that the use of live vaccines in such
subpopulations poses serious difficulties [4,5]. The greatest
disadvantage of subunit vaccines is their general requirement for
strong adjuvants, as these adjuvants often induce detrimental tissue
reactions. Lastly, the concept of so-called killed but metabolically
active (KBMA) bacteria involves bacteria which are unable to
form colonies on growth media but still have an intact protein
synthesis and secretion machinery. Such mutants are reportedly
capable of inducing CD4+ and CD8+ T cell responses and
protection [3]. However this requires multiple injections.
Lm is a facultative intracellular microorganism and many of the
bacterial determinants necessary for pathogenesis, including
intracellular growth and spread of Lm, have been identified and
are clustered on a 10-kb region of the chromosome termed the
virulence gene cluster (vgc) which encodes the prfA, plcA, hly, mpl,
actA and plcB genes organized in three transcriptional units [6].
Being a facultative intracellular bacterium makes Lm particu-
larly attractive as a potential live vaccine vector for the induction
of cell-mediated immunity to foreign antigens [7,8]. However,
despite its capability to induce effective CD8+ T-cell responses the
safety of recombinant Lm remains an important issue, as infections
with Lm can cause severe and life-threatening infections [9].
Moreover, infection with Lm is mainly accompanied by undesired
CD4+ T-cell mediated delayed type hypersensitivity (DTH)
responses and granulomatous inflammation [10,11]. Therefore
the use of Lm in a clinical setting is associated with major risks
limiting its potential as an effective vaccine vector.
An alternative strategy would entail the transfer of a core set of
virulence genes from pathogenic Lm to create a strain that is
attenuated for virulence but is capable of inducing an effective
immune response. To explore this approach we have transferred
the vgc locus of Lm into a non-pathogenic species of Listeria such as
L. innocua (L.inn) as a carrier strain. Here we show that a single
immunization with this recombinant strain (L.inn::vgc) fulfills the
desired requirements for a successful bacterial vaccine vector.
These include low virulence in association with induction of
protective antigen-specific CD8+ T-cell responses and reduction of
CD4+ T cell-mediated inflammation.
Results
In vivo survival of the recombinant L.inn::vgc strain
The ability of Listeria to survive in vivo at the early stage of
infection is crucial for the induction of cell-mediated immunity
[12,13]. We examined the ability of L.inn::vgc to survive in the
spleen and liver in infected mice and compared it to that of the
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wild type Lm. BALB/c mice were infected intravenously (i.v.) with
sub-lethal doses of wild type Lm EGD-e (103), L.inn::vgc (107), or the
wild type L.inn strain (107). Time points correlating with the critical
phases of host immune response to listerial infection were selected
and used to compare bacterial growth and induction of immune
effectors in wild-type Lm, L.inn and L.inn::vgc strains. Day 3 of a
Listeria infection refers to the end of the pre-immune phase before
the expansion of specific T cells in the mouse model of listeriosis
[14]. The presence of viable bacteria on this day has been shown
to be critical for the successful induction of T cell-mediated
immunity [15]. Therefore on day 3, bacterial load as well as spleen
morphology was analyzed. Day 9 corresponds to the primary
immune effector phase. At this time point, DTH to soluble antigen
was measured in vivo as an indicator of DTH reaction and CD4+ T
cell activity. Moreover, the numbers of antigen specific IFN-c
producing CD8+ cytotoxic T cells were analyzed. Day 60 post-
infection as well as day 5 post-challenge were chosen to analyze
the memory immune effector phase [16]. To this end the number
of memory effector T- cells was determined quantitatively.
In vivo survival and growth kinetics of bacteria were followed by
determining the number of bacteria in spleens and livers of
infected mice. As expected, regardless of the dose of infection, the
wild type L.inn strain was progressively cleared from both organs
(Fig. 1A) whereas the L.inn::vgc strain successfully survived in both
spleen and liver during the first two days after infection as
indicated by the bacterial numbers that increased in both spleen
and liver till day 2 and gradually decreased over days 3 and 4 post-
infection. On the other hand, the bacterial numbers of the wild
type Lm, increased from day 1 till day 4 post-infection in both
spleen and liver.
Stimulation of Type I interferon’s by the L.inn::vgc strain
A striking phenomenon for cytosolic resident microbes is the
ability to induce expression of Type I interferons. In contrast to the
wild type Lm, its isogenic mutant lacking listeriolysin remains
trapped in vacuoles and does not induce Type I interferon’s [17].
We have recently documented that the L.inn::vgc can successfully
survive inside phagocytic cells, thereby egressing from the
phagolysosome [18]. In order to confirm if cytosolic persistence
of the recombinant L.inn::vgc strain is efficient enough to stimulate
production of such cytokines, we examined the transcriptional
responses of IFN-a2 and IFN-b1 in bone marrow-derived
macrophages following infection with Lm, L.inn as well as the
recombinant L.inn::vgc strain. L.inn::vgc and the wild type Lm showed
significantly higher transcriptional induction of both IFN-a2 and
IFN-b1 than wild type L.inn at 2 hours post-infection (Fig. 1B).
This effect was more pronounced at a later time point (8 hours)
post-infection reflecting the efficient intracellular survival pattern
of the L.inn::vgc strain.
The recombinant L.inn::vgc strain exhibits a lowered
inflammatory response
At the early stages of infection, wild type Lm is engulfed by
professional phagocytes like macrophages, dendritic cells, or
neutrophils. These cells produce a variety of proinflammatory
cytokines which recruite or activate other inflammatory immune
cells. The levels of IL-1ß, IL-6, IL-12, and TNF-alpha in mice sera
were measured over the first 4 days after infection with Lm (103),
L.inn (107), and the L.inn::vgc strain (107). Like L. inn, , L.inn::vgc was
not able to produce significant amounts of these cytokines over the
first 4 days post-infection in spite of high infection doses (107) while
primary infection with Lm led to high proinflammatory cytokine
production (Fig. 2).
Both granuloma formation and delayed-type-hypersensitivity
footpad responses have previously been shown to be CD4+ T cell
dependent inflammatory responses following infection with Lm.
Morphological changes were examined in the spleens on day 3
after i.v. infection. Although the numbers of bacteria in spleens at
day 3 post-infection for both Lm and L.inn::vgc were approximately
the same (Fig. 1A), distinct differences in the morphological
appearance between spleens isolated from mice infected with Lm
and those isolated from mice infected with L.inn::vgc were observed
(Fig. 3A). Splenomegaly associated with extensive granuloma
formation was observed in spleens of Lm infected mice, as a result
of intensive leukocyte infiltration which was visualized in stained
spleen sections (Fig. 3B), whereas splenomegaly in the absence of
granuloma formation was observed in spleens of L.inn::vgc infected
mice. Infection with the wild type L.inn did not result in any
morphological changes in spleens.
These observations were confirmed by antigen-elicited skin
responses showing corresponding results (Fig. 3C). Mice were
injected into the left hind footpads with 50 ml of somatic soluble
Lm EGD-e antigen (60 ng/ml) at day 9 post-infection. Twenty-
four hours later, thickness of the left and right footpads of
individual mice were measured. Footpads of mice pre-immunized
with L.inn::vgc showed reduced thickness than those of mice pre-
immunized with the wild type Lm. The wild type L.inn strain did
not induce a DTH response in the footpads of these mice.
Moreover, antigen-induced CD4+ T cell-derived IFN-gamma
production of spleen cells was measured as an indication for a pro-
inflammatory T cell response. Spleen cells were isolated at day 9
post-infection and stimulated in vitro with the released soluble
antigen of L. monocytogenes EGD-e (100 ng). Spleen cells from mice
immunized with L.inn::vgc produced significantly lower levels of
IFN-gamma when compared to spleen cells from mice immunized
with wild type Lm. The wild type L.inn strain failed to prime T
cells for the production of IFN-gamma (Fig. S1, supplementary
information).
Induction of T cell-mediated immunity by the
recombinant L.inn::vgc strain
A number of cell types are involved in host defense against
Listeria. Antigen-specific T lymphocytes mediate recovery from
primary listerial infections and protective immunity to subsequent
infections [13,19]. Both CD4+ (helper, MHC class II restricted)
and CD8+ (cytotoxic, MHC class I restricted) T cell subpopula-
tions have been implicated [20]. Experimental evidence indicates,
however, that CD8+ T cells play the predominant role in
mediating protective immunity [21–24]. The ability of the
recombinant L.inn::vgc to induce T-cell mediated immunity as a
prerequisite for protective immunity was analyzed. Groups of
BALB/c mice were infected with Lm (103), L.inn (107), or L.inn::vgc
(107). Two months later, all mice were challenged with a lethal i.v.
dose (105), corresponding to 206LD50, of the wild type Lm, and
survival was monitored. As controls, a group of untreated BALB/c
mice that received a similar lethal dose of the wild type Lm were
included. A single pre-immunization with the L.inn::vgc strain led to
a significant protection against subsequent lethal infection with Lm.
As expected, all mice that were pre-immunized with sub-lethal
doses of Lm were also protected against a lethal listerial infection
and survived whereas all non-immunized mice as well as those pre-
immunized with L.inn died within 4 days after challenge (Fig. 4A).
Entry of Listeria into the cytosol is a critical event for CD8+ T
cell recognition and induction of immunity [22]. In order to
establish the correlation between the protection of mice pre-
infected with Lm or the L.inn::vgc strain upon lethal challenge and
the induction of CD8+ T cells in response to infection, the
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generation of antigen-specific MHC class I restricted CD8+ T cells
were quantitatively examined. The numbers of antigen-specific
MHC class I restricted effector CD8+ T cells induced in mice
spleens 9 days after primary infection and 5 days after challenge
with the wild type Lm (26103) was determined through evaluation
of the number of IFN-c producing CD8+ T cells induced showing
reactivity against the dominant H-2Kd restricted LLO91–99
epitope [25] in an in vitro ELISPOT assay. As shown in Fig. 4B,
infection with wild type Lm as well as the L.inn::vgc strain induced
significant numbers of LLO91–99 specific CD8
+ T-cells. After recall
infection the numbers of LLO91–99 specific CD8
+ T-cells showed a
significant increase. On the other hand, infection with L.inn failed
to induce a significant number of CD8+ T-cells either after
primary infection or after challenge.
To address the contribution of effector memory CD8+ T cells in
mediating long-lasting immunity after re-infection with the wild
type Lm, the expression level of the cell surface adhesion molecule
CD62L was quantified. Expression of CD62L is down regulated
on the surface of cytotoxic CD8+ T-cells when developed to
protective memory T cells [21]. Two months after the primary
infection, the number of CD8+CD62Llo lymphocytes was
approximately identical in all groups of primarily infected mice.
This number increased dramatically upon re-infection with the
wild type Lm (26103) in mice pre-immunized with Lm as well as
with L.inn::vgc while pre-immunization with L.inn was not able to
induce CD62L down-regulation seen in the other groups (Fig. 5).
In addition we have monitored the expression of CD44 on CD8+
T-cells. CD44 is expressed at high levels on memory but not in
naı¨ve T-cells [26]. In mice that were primarily infected with Lm
and L.inn::vgc, the expression of CD44 was upregulated on CD8+
T-cells 5 days post-challenge infection with the wild type Lm
(26103) while primary infection with L.inn did not lead to a
significant change in CD44 expression pattern (Fig. S3).
Discussion
In this study, we define a unique vaccine strategy which is based
on a rationally designed pathogen by complementation of a non-
Figure 1. Bacterial load and IFN expression during the course of primary infection. A. Course of primary infection in mice with the wild
type Lm (EGD-e) and the recombinant L. inn::vgc strain. Mice were infected i.v. with 103 cfu Lm, 107 cfu L.inn, or 107 cfu L.inn::vgc strains. At different
time intervals after the infection, mice were sacrificed and the number of viable bacteria in the organs was enumerated. B. Quantitative measurement
of IFNa2 and IFNb1 expression in bone marrow-derived macrophages using RT-PCR at 2 h and 8 h following infection with Lm , L.inn, or the L.inn::vgc
strains. *P,0.05 (L.inn vs. Lm and L.inn::vgc strains).
doi:10.1371/journal.pone.0035503.g001
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pathogenic strain with selected genes necessary to induce a
vigorous immune response. To illustrate the proof of principle of
this strategy we used the Listeria model by taking a non-pathogenic
L.inn strain and complementing it with genes from pathogenic Lm
which were previously shown to be a sine qua non requirement for
intracellular growth and survival [18]. This novel vaccine strategy
resulted in generation of a recombinant strain (L.inn::vgc) that
possesses properties needed to induce the marked protective
immunogenic properties of the wild type Lm but is attenuated in
virulence as well as in its capacity to induce host detrimental cell-
mediated inflammation. The recombinant L.inn::vgc strain showed
a significant in vivo survival rate in the first 3 days post-infection
(Fig. 1A). This observation is in accordance with our recent finding
that the L.inn::vgc strain is able to survive in phagocytic host cells
[18]. Moreover, it has the capability to induce identical Type I
interferon at levels similar to wild type Lm. As previously shown by
McAffrey et al., 2003, induction of type 1 IFN is a surrogate
marker indicating access of Listeria into the cytosol of antigen
presenting cells [17]. We have shown that the L.inn::vgc strain could
use the complemented virulence factors to escape into the cytosol
and subsequently be presented to CD8 T lymphocytes. In this
context Zwaferink et al. 2008 have shown a role for IFNb in
macrophage cell death. Treatment of macrophages with this
cytokine could enhance host-cell membrane permeabilization by
listeriolysin consequently leading to cell apoptosis [27].
Especially encouraging was the observation that, although
L.inn::vgc strain was injected at a high dose of 107 cfu, mice could
still efficiently control the infection and showed very low blood
levels of pro-inflammatory cytokines thus reducing the detrimental
inflammatory responses caused by the wild type Lm. Morpholog-
ical and histological analysis of spleen after infection with Lm have
shown the induction of splenomegaly and granuloma as a result of
monocytic infiltrations of the white pulp which were most
pronounced on day 3 post-infection while infection with L.inn::vgc
only resulted in a splenomegaly without any significant morpho-
logical changes detectable (Fig. 3A,3B). The intensity of the
morphological and histological alterations in spleens paralleled the
level of Listeria-induced DTH responses, as the in vivo induction of
DTH after L.inn::vgc infection was also significantly lower than
DTH induction following Lm infection (Fig. 3 and Fig. S1). We
therefore show that the recombinant L.inn::vgc strain shows a
significantly reduced proinflammatory and CD4+ mediated
Figure 2. Measurement of proinflammatory cytokine levels in serum. Sera was obtained from mice on days 1, 2, 3, and 4 post-infection after
inoculation with 103 cfu Lm, 107 cfu L.inn, or 107 cfu L.inn::vgc. Levels of IL-1ß, IL-6, IL-12(p70), and TNF-alpha were quantified using a multiplex
cytokine assay kit. *P,0.05 (EGD-e vs. L.inn and L.inn::vgc strains).
doi:10.1371/journal.pone.0035503.g002
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inflammatory response compared to Lm, thereby addressing one
major concern regarding the use of live Lm as a vaccine.
However the crucial question remained as to whether the
L.inn::vgc strain elicits significant adaptive immune responses
resembling those of the wild-type strain. Since Lm is located in
both phagosomes and cytosol of professional antigen-presenting
cells during infection, epitopes derived from Listeria proteins are
presented by the MHC pathway thereby priming both effector
CD4+ and CD8+ T cells [28,29] resulting in full elimination of
Listeria from the host. Previous experimental studies [30,31] have
revealed that persistence and number of viable microorganisms
are important parameters for establishing efficient T cell-mediated
immunity. Moreover, it has been shown that the presence of live
bacteria in mice organs over the first 48 hours after immunization
is critical for the induction of effector CD8+ T cell mechanisms
[32]. Indeed we were able to show that all animals immunized
with Lm or L.inn::vgc were protected against 206LD50 of virulent
Listeria (Fig. 4A). Although the L.inn::vgc strain elicits lowered CD4+
mediated inflammatory responses as compared to infection with
Lm, it is capable of mounting a successful anti-listerial protective
response, indicating that the observed in vivo survival pattern of the
L.inn::vgc strain was sufficient to induce protection.
The entry of effector T cells into a memory stage, however, is
accompanied by the ability to rapidly expand their population
during recall responses and to down regulate expression of cell
surface markers such as CD62L and CCR7 [33]. It was previously
reported that primary infection with the wild type Lm induces
down regulation of CD62L on the surface of effector CD8+ T cells
which reaches its lowest levels at day 8 post-infection [34].
However, over the following weeks, expression of CD62L is up
regulated. During recall infection, CD62L is then rapidly down
regulated on the surface of memory CD8+ T cells [32,35]. In order
to correlate protection against challenge with Listeria with antigen
specific CD8+ T cells, we examined the induction of LLO91–99
specific CD8+ T cells in response to primary infection with the
different Listeria strains. Infection with L.inn::vgc induced a
significant population of cytotoxic CD8+ T lymphocytes (Fig. 4B)
which, upon challenge with the wild type Lm, showed a CD62L
expression pattern similar to that presented in mice primarily
infected with the wild type Lm (Fig. 5). The identity of the memory
T-cells induced in response to L.inn::vgc infection was confirmed by
testing the CD44 expression on the CD8+ T-cells following recall
infection with Lm where high expression of CD44 was observed on
CD8+ T-cells derived from mice primarily infected with the
recombinant L.inn::vgc strain but not with the wild type L.inn (Fig.
S3). The inability of the Lm strain lacking listeriolysin O (LLO)
[36] as well as the L.inn strain expressing only LLO [37] to induce
a protective T cell response reflects the requirement of the entire
virulence gene cluster in conferring a long lasting immunity. We
therefore show that a non-pathogenic L.inn strain complemented
Figure 3. Examination of spleens and DTH response after infection with Lm and the recombinant L.inn::vgc strain. A. Morphological
examination of spleens from mice inoculated i.v. with the wild type Lm and the recombinant L.inn::vgc strain. Spleens of mice infected i.v. as
mentioned in Fig. 1 were isolated on day 3 after infection. Shown is a spleen from mice infected with the wild type Lm, the wild type L.inn and its
recombinant mutant strain L.inn::vgc. Infiltration of monocytic cells and granulomatous lesions are only detectable in the spleens isolated from mice
infected with the wild type Lm. B. Spleen sections were stained with HE and examined. Granulomas with massive leukocyte aggregates can only be
detected in spleens of mice infected with Lm. C. DTH response to listerial antigen 9 days after primary infection. Mice were infected with 103 CFU of
Lm, 107 CFU of L.inn, or 107 CFU of L.inn::vgc strain. 9 days after infection, DTH was triggered through injection of soluble somatic listerial antigen.
Twenty-four hours later, the specific skin response was determined. The mean value 6 S.E. of five animals of a representative experiment is
shown.*P,0.05 (EGD-e vs. L.inn::vgc strain).
doi:10.1371/journal.pone.0035503.g003
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Figure 4. Protective immunity and cellular immune response after infection with Lm and the L.inn::vgc strain. A. Induction of protective
immunity conferred after infection with the L.inn::vgc strain. Groups of 15 mice were infected i.v. as described in Fig. 1. Two months later all mice were
challenged with a lethal dose (206LD50) of the wild type Lm. As a control, a group of uninfected normal mice was included. Survival of mice after the
challenge was monitored up to 8 days. B. Number of antigen-specific IFN-gamma producing CD8+ T cells in spleens of mice infected i.v. with the wild
type Lm, L.inn and L.inn::vgc strain determined by ELISPOT. Spleen cells from infected mice were isolated either on day 9 after the primary infection or
day 5 after challenge infection and stimulated with the immunodominant MHC class I peptide LLO91–99 in triplicates in nitrocellulose based 96-well
culture plates. Number of specific IFN-gamma producing cells against the dominant H-2Kd restricted LLO91–99 epitope were determined by counting
the number of spots under the microscope. *P,0.05 (L.inn vs. Lm and L.inn::vgc strains).
doi:10.1371/journal.pone.0035503.g004
Figure 5. Expression levels of CD62L on CD8+ splenocytes following primary and recall infection with Lm, L.inn and the L.inn::vgc
strain. Flow cytometry was performed on spleen cells, isolated from mice on day 60 after the primary infection or day 5 after the challenge. Cells
were stained with FITC-labelled anti-Lyt-2 and biotinylated anti-CD62L. The binding of anti-CD62L on the cell surface was detected with PE-
conjugated streptavidin. Numbers shown are gated CD8+CD62lo T cells and analyzed with CELLQuest software.
doi:10.1371/journal.pone.0035503.g005
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with the entire vgc is capable of inducing a vigorous anti-listerial
response.
Even though we have demonstrated a vigorous immune
response following i.v. infection the immune response to Listeria
can vary considerably depending on the route of administration.
Using the intraperitoneal route of infection, we obtained a similar
result i.e. protection following pre-infection with the Lm and L.
inn::vgc strains but not with mice pre-immunized with the L. inn
strain (Fig. S2). Thus despite a different route of infection Lm::vgc is
able to induce protection in-vivo. The mouse is not a suitable and
reproducible model for evaluating oral immunization protocols
because of the specificity of the listerial InlA molecule [38].
Therefore experiments examining mucosal immunity will have to
be carried out in the guinea pig model of listerial infection.
Recently, highly attenuated mutants of Lm have been developed
as candidates for vaccine vectors [3,39], however, a single
immunization with these strains was not sufficient for the
induction of protective cellular immunity.
Here a transcomplemented strain of a non-pathogenic L. inn
strain expressing genes of the vgc cluster provides robust protection
with a single dose of 107 cfu bacteria without causing any signs of
overt illness. The LD50 of the wild type Lm is around 5000 cfu. As
shown in figure 1A, the L.inn::vgc strain does not grow in-vivo
beyond day 3 post-infection and is subsequently eliminated. These
properties, imparting protective responses and rapid elimination
from the host are considered to be desirable properties for
successful vaccine vectors. Our results, namely, the in vivo survival
pattern, the induction of interferon’s and antigen specific CD8+ T
cells, the lack of overt detrimental inflammatory reactions and
most importantly the induction of protection against challenge
with Listeria, allow the conclusion that the L.inn::vgc strain is
potentially capable of inducing protection and that further
development of this strain as a suitable live bacterial vaccine
vector in clinical settings are warranted.
Materials and Methods
Ethics Statement
Mice experiments were done according to the requirements of
Justus-Liebig University Giessen Animal Ethics Committees with
ethics approval number: 63/2007. Animals were sacrificed using
CO2 asphyxiation and the appropriate organs aseptically
harvested.
Mice
Six to eight week-old female BALB/c mice, purchased from
Harlan Winkelmann (Borchen, Germany), were kept at our
breeding facilities in specific-pathogen-free conditions and used in
all experiments.
Bacteria
Bacterial strains used in this study are wild type Listeria
monocytogenes EGDe serotype 1/2a (Lm) [40], wild type L. innocua
strain (serotype 6a NCTC 11288) [41] transformed with either the
recently characterized gram+ve/gram-ve shuttle pUvBBAC+vgc1
vector and referred to as (L.inn::vgc strain) or the pUvBBAC vector
without the inserted vgc and referred to as L.inn [18] Bacteria were
grown in brain-heart infusion (BHI) (Difco, Augsburg; Germany)
broth in presence or absence of 5 mg/ml erythromycin. For each
experiment, erythromycin was used as a selective antibiotic for
growth of L.inn::vgc and the wild type L.inn harbouring the
pUvBBAC vector. Wild type L. monocytogenes was grown in
absence of erythromycin. In all experiments, fresh cultures of
bacteria, prepared from an overnight culture, were used. Briefly,
bacteria were grown in Brain Heart Infusion (BHI) at 37uC,
harvested in the exponential growth phase and washed twice with
PBS. The pellet was resuspended in PBS and the bacterial
concentration was calibrated by optical absorption. Further
dilutions were prepared in PBS to obtain required numbers of
bacteria for infection.
In vitro infection assay
The protocols for animal handling were previously approved by
our institutional Animal Ethics Committee (protocol number 63/
2007). Bone marrow-derived macrophages were isolated from 4 to
6 week old C57Bl/6 female mice and grown and differentiated for
7 days in L929 conditioned medium to an approximate
concentration of 2,56105 cells/well in 6-well plates. On the day
of infection the medium was exchanged against MDEM medium
with 1% FCS and the cells were infected with 56106 cfu per well
with the wild type Lm and L.inn strains as well as the recombinant
L.inn::vgc strain for 2 h and 8 h. The cells were lysed and their total
RNA was isolated.
RNA isolation
For every bacterial strain and negative control the cells of at
least two wells of a six well tissue culture plaque were lysed and
total RNA was isolated. Prior to lysis culture medium was
aspirated and cells were lysed using RLT lysis buffer (Qiagen,
Germany). Total RNA was isolated using the RNeasy Mini Kit
and the RNase free DNase I set (Qiagen) following the
manufacturers protocol. The RNA was recovered in RNase free
water, heat denatured for 10 min. at 65uC; quantified with the
NanoDropH ND-1000 UV-Vis Spectrophotometer (NanoDrop
Technologies, USA) and a quality profile with the Agilent 2100
bioanalyzer (Agilent Technologies, Germany) was made.
Real time RT-PCR
First-strand cDNA was synthesized with 500 ng of purified
RNA using SuperScriptII (Invitrogen) and a mixture of T21 and
random nonamer primers (Metabion) following the instructions for
the reverse transcription reaction recommended for the Quanti-
Tect SYBR Green PCR Kit (Qiagen). Real-time quantitative PCR
was performed on an ABI Prism 7700 real time cycler. The
relative expression of the targets IFNa2 (Interferon alpha 2) and
IFNb1 (Interferon beta) were normalized to that of two reference
genes: SDHA (Succinate dehydrogenase alpha subunit) and PPIA
(peptidylprolyl isomerase A). Finally a mean of the fold change of
the target versus each of the reference genes was taken as the final
value.
Somatic bacterial antigens
Somatic soluble antigen was prepared by culturing Lm in tryptic
soy broth for 18 h, washing it in PBS, and subsequently subjecting
it to ultrasonication.1 g (wet weight) of bacterial cells were
suspended in 10 ml of PBS and sonicated five times for 1 min
(87.5%, output, degree 7 on a sonifier model S-125; Branson Sonic
Power, USA) on ice. The sonicated suspension was centrifuged at
39 000 U for 50 min, and the supernatant was filter sterilized
(pore size,0.45 mm) and stored at 220uC at a dilution of 1:100 in
PBS [42].
Experimental infection and determination of bacterial
load in infected organs
Primary in vivo infection with Lm (103), the wild type L.inn (107),
or the L.inn::vgc (107) strain was performed by an intravenous
injection of viable bacteria in a volume of 0.2 ml PBS. Bacterial
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growth in spleens and livers was determined by plating 10-fold
serial dilutions of the organ homogenates on BHI agar plates. The
detection limit of this procedure was 102 colony forming units
(CFU) per organ. Colonies were counted after 24 h of incubation
at 37uC.
Measurement of cytokines production
Cytokine production was assayed from the collected sera of
infected mice using a multiplex cytokine assay kit and Luminex
technology (Bio-Rad). Balb/C mice were infected with Lm (103),
the wild type L.inn (107), or the L.inn::vgc (107) strain. Sera were
aseptically isolated on days 1, 2, 3, and 4 post-infection. Four
cytokines were tested: TNFa, IL-1b, IL-6, and IL-12(p70) and
cytokine levels were presented as absolute concentrations in pg/
ml.
Histology
Spleens were aseptically isolated from mice previously infected
with the different Listeria strains as mentioned above and examined
for morphological alterations. Tissues were fixed in 10% neutral
buffered formalin, embedded in paraffin, sectioned, and 5 mm
sections were stained with hematoxylin and eosin (HE). Patho-
plogical foci in spleen sections were then microscopically examined
(Keyence).
Estimation of antigen specific IFN-c producing cells
Spleens were aseptically removed from mice at day 9 post-
infection with the wild type Lm, the wild type L.inn, or the L.inn::vgc
strain. Spleen cells were isolated and antigen (LLO91–99) specific
IFN-c producing CD8+T cells were determined in the spleens of
mice after i.v. infection with the same bacterial strains mentioned
above by using an ELISPOT system as previously described
[23,35].
Quantification of IFN-gamma in cell culture supernatants
IFN-gamma was measured in the supernatants of splenocytes by
using a mouse IFN-gamma ELISA kit, BD optEIATM (BD
Biosciences Pharmigen) according to the manufacturer instruc-
tions. The assay was performed in duplicates, and data represent
means 6 standard error.
Flow cytometry analysis
For flow cytometry analysis, approximately 16106 splenocytes,
isolated from infected mice (Lm, L.inn, and L.inn::vgc strains) were
stained with FITC labelled anti-CD8 and biotinylated anti-
CD62L or anti-CD44 (pharMingen, Becton Dickinson). PE-
conjugated streptavidin was used to detect the binding of anti-
CD62L or anti-CD44 on the cell surface. Flow cytometry was
performed using a FACS Calibur flow cytometer and further
analyzed with CELL Quest software (Becton Dickinson, CA).
Protection studies
All mice, pre-immunized with wild type Lm, the wild type L.inn
strain and the L.inn::vgc strain were challenged 2 months later with
a 206LD50 (10
5) lethal dose of wild type Lm. A group of non pre-
immunized Balb/c mice were included as controls. Survival of
mice was monitored for several days and expressed as percentage
of animals surviving challenge with Lm.
Statistical analysis
Data are representative of at least three independent experi-
ments. Significance of the represented data was calculated using
ANOVA (analysis of variance). Data are expressed as mean 6
standard errors (S.E.).
Supporting Information
Figure S1 Listeria-induced IFN-gamma production by
spleen cells 9 days after infection (i.v.). Mice were infected
with 103 CFU of Lm, 107 CFU wild type L.inn, or with 107 CFU
of L.inn::vgc strain. On day 9 after infection, mice were killed and
spleens removed. Single cell suspensions were stimulated in vitro
with secreted soluble Listeria antigen to produce IFN-gamma. After
48 hours, culture supernatants were tested for presence of IFN-
gamma by ELISA. *P,0.05 (EGD-e vs L.inn::vgc).
(TIF)
Figure S2 Intraperitoneal infection with the L.inn::vgc
strain induces protective immunity. Mice were infected
intraperitoneally with Lm, L.inn and the L.inn::vgc strain as
described in figure 4A. After 2 months all mice were challenged
i.v. with a lethal dose (206LD50) of the wild type Lm. As a control,
a group of uninfected normal mice was included. Survival was
monitored up to 8 days after challenge.
(TIF)
Figure S3 Quantification of CD44 expression on CD8+
splenocytes following primary and recall infection with
Lm, L.inn and the L.inn::vgc strain. Flow cytometry was
performed on spleen cells, isolated from mice on day 60 after the
primary infection or day 5 after the challenge. Cells were stained
with FITC-labelled anti-Lyt-2 and PE-labelled anti-CD44.
Numbers shown are gated CD8+CD44hi T cells and analyzed
with CELLQuest software.
(TIF)
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